1887

Abstract

The pandemic coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) is a global health problem. COVID-19 has given rise to a number of secondary bacterial or fungal infections. During the second wave of COVID-19, India experienced an epidemic of mucormycosis in COVID-19 patients. In this paper, we discuss the clinical features, investigations and management of four patients having COVID-19-associated mucormycosis (CAM), especially rhino-orbital mucormycosis (ROM) caused by and species. We also compare the cases and their risk factors with previously reported CAM cases in India. Three patients had mucormycosis after recovering from COVID-19. They were successfully treated with surgical debridement and early initiation of anti-fungal therapy with systemic amphotericin B and other supportive measures such as broad-spectrum antibiotics, insulin infusion, antihypertensives and analgesics. The remaining patient had mucormycosis during COVID-19. He was admitted in the intensive care unit due to COVID-pneumonia and was on mechanical ventilation. In spite of all supportive measures, the patient succumbed to death due to cardiogenic shock. Three out of our four patients had diabetes mellitus. All patients were treated with systemic steroid during COVID-19 treatment. Diabetes mellitus and steroid treatment are the major risk factors for CAM. Early diagnosis of this life-threatening infection along with strict control of hyperglycemia is necessary for optimal treatment and better outcomes.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial License. The Microbiology Society waived the open access fees for this article.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000360
2022-06-06
2022-06-25
Loading full text...

Full text loading...

/deliver/fulltext/acmi/4/6/acmi000360.html?itemId=/content/journal/acmi/10.1099/acmi.0.000360&mimeType=html&fmt=ahah

References

  1. Nehara HR, Puri I, Singhal V, Ih S, Bishnoi BR et al. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: case series from the north-western part of India. Indian J Med Microbiol 2021; 39:380–383 [View Article] [PubMed]
    [Google Scholar]
  2. Chakrabarti A. The recent mucormycosis storm over Indian sky. Indian J Med Microbiol 2021; 39:269–270 [View Article] [PubMed]
    [Google Scholar]
  3. Roy A. Make mucormycosis a notifiable disease under epidemic act, urges centre; 2021 https://www.hindustantimes.com/india-news/make-mucormycosis-a-notifiable-disease-under-epidemic-act-urges-centre-101621501157362.html accessed 4 June 2021
  4. Muthu V, Rudramurthy SM, Chakrabarti A, Agarwal R. Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathologia 2021; 186:739–754 [View Article] [PubMed]
    [Google Scholar]
  5. Montgomery DJ, Goldstein RS, Douse DM, Tuitt J, Sinnott M. An indolent case of isolated cerebral mucormycosis: an uncommon presentation. Access Microbiol 2019; 1:e000023 [View Article] [PubMed]
    [Google Scholar]
  6. Chander J. Textbook of Medical Mycology, 2nd edn. New Delhi, India: Jaypee Brothers Medical Publishers; 2017
    [Google Scholar]
  7. Mishra Y, Prashar M, Sharma D, Kumar VP et al. Diabetes, COVID 19 and mucormycosis: clinical spectrum and outcome in a tertiary care medical center in western India. Diabetes Metab Syndr 2021; 15:102196 [View Article]
    [Google Scholar]
  8. Malhothra S, Mandal S, Meena R, Patel P, Bhatia NK et al. A treated case of rhinocerebral zygomycosis with aspergillosis: a case report from India. Access Microbiol 2020; 2:000139 [View Article] [PubMed]
    [Google Scholar]
  9. Liu M, Spellberg B, Phan QT, Fu Y, Fu Y et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 2010; 120:1914–1924 [View Article]
    [Google Scholar]
  10. Gebremariam T, Liu M, Luo G, Bruno V, Phan QT et al. CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest 2014; 124:237–250 [View Article]
    [Google Scholar]
  11. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021; 15:102146 [View Article]
    [Google Scholar]
  12. Chandra S, Rawal R. The surge in Covid related mucormycosis. J Infect 2021; 83:381–412 [View Article]
    [Google Scholar]
  13. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395:1417–1418 [View Article] [PubMed]
    [Google Scholar]
  14. John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi (Basel) 2021; 7:298 [View Article] [PubMed]
    [Google Scholar]
  15. Muniangi-Muhitu H, Akalestou E, Salem V, Misra S, Oliver NS et al. Covid-19 and diabetes: a complex bidirectional relationship. Front Endocrinol (Lausanne) 2020; 11:758 [View Article] [PubMed]
    [Google Scholar]
  16. Wu C-T, Lidsky PV, Xiao Y, Lee IT, Cheng R et al. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell Metab 2021; 33:1565–1576 [View Article] [PubMed]
    [Google Scholar]
  17. Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg Infect Dis 2021; 27:2349–2359 [View Article] [PubMed]
    [Google Scholar]
  18. Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomes of reported cases. Med Mycol 2018; 56:29–43 [View Article] [PubMed]
    [Google Scholar]
  19. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019; 19:e405–e421 [View Article] [PubMed]
    [Google Scholar]
  20. Pal R, Singh B, Bhadada SK, Banerjee M, Bhogal RS et al. COVID-19-associated mucormycosis: an updated systematic review of literature. Mycoses 2021; 64:1452–1459 [View Article] [PubMed]
    [Google Scholar]
  21. Tandon N, Anjana RM, Mohan V, Kaur T, Afshin A et al. The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990-2016. Lancet Glob Health 2018; 6:e1352–e1362 [View Article] [PubMed]
    [Google Scholar]
  22. Rudramurthy SM, Singh G, Hallur V, Verma S, Chakrabarti A. High fungal spore burden with predominance of Aspergillus in hospital air of a tertiary care hospital in Chandigarh. Indian J Med Microbiol 2016; 34:529–532 [View Article] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/acmi/10.1099/acmi.0.000360
Loading
/content/journal/acmi/10.1099/acmi.0.000360
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error